Kwonjune J. Seung
Kwonjune J. Seung has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Carole D. Mitnick
Partners Hlth, Boston, MA USA
2 shared publicationsCatherine Hewison
Med Sans Frontieres, Dept Med, Paris, France
2 shared publicationsHelena Huerga
Epictr, Field Epidemiol Dept, Paris, France
2 shared publicationsMolly F. Franke
Partners Hlth, Boston, MA USA
2 shared publications- Molly Forrest Franke
Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA
2 shared publications Salmaan Keshavjee
Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts 02115 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts 02115 Partners In Health, Boston, Massachusetts 02215
2 shared publications
Latest Publications
- 14 May 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (2) , 583
Corrigendum to ‘High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients’ [J Hepatol 72 (2020) 1028–1029]
- 14 May 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (2) , 583
Corrigendum to ‘High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients’ [J Hepatol 72 (2020) 1028–1029]
- 1 May 2020
- Published by Elsevier in Journal of Hepatology
- Vol. 72 (5) , 1028-1029
High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients
- 1 May 2020
- Published by Elsevier in Journal of Hepatology
- Vol. 72 (5) , 1028-1029
High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients
- Open Access
- 20 August 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-9
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment landscape. However, despite their availability for routine programmatic use, the uptake of these drugs has remained slow; concerns included a lack of evidence on safety and efficacy and the need to protect the new drugs from the development of acquired resistance. As part of the endTB Project, we aimed to address these barriers by generating evidence on safety and efficacy of bedaquiline or delamanid based MDR-TB regimens. This is a protocol for a multi-center prospective cohort study to enroll 2600 patients from April 2015 through September 2018 in 17 countries. The protocol describes inclusion of patients started on treatment with bedaquiline- or delamanid- containing regimens under routine care, who consented to participate in the endTB observational study. Patient follow-up was according to routine monitoring schedules recommended for patients receiving bedaquiline or delamanid as implemented at each endTB site. Therefore, no additional tests were performed as a part of the study. Data were to be collected in a customized, open-source electronic medical record (EMR) system developed as a part of the endTB Project across all 17 countries. The endTB observational study will generate evidence on safety and efficacy of bedaquiline- and delamanid-containing regimens in a large, extremely heterogeneous group of MDR-TB patients, from 17 epidemiologically diverse countries. The systematic, prospective data collection of repeated effectiveness and safety measures, and analyses performed on these data, will improve the quality of evidence available to inform MDR-TB treatment and policy decisions. Further, the resources available to countries through implementation of the endTB project will have permitted countries to: gain experience with the use of these drugs in MDR-TB regimens, improve local capacity to record and report adverse events (pharmacovigilance), and enhance significantly the body of data available for safety evaluation of these drugs and other novel treatments. This study was registered on 24 August 2017 at clincaltrials.gov (Registration number: NCT03259269).
- 20 August 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-9
Open AccessThe endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment landscape. However, despite their availability for routine programmatic use, the uptake of these drugs has remained slow; concerns included a lack of evidence on safety and efficacy and the need to protect the new drugs from the development of acquired resistance. As part of the endTB Project, we aimed to address these barriers by generating evidence on safety and efficacy of bedaquiline or delamanid based MDR-TB regimens. This is a protocol for a multi-center prospective cohort study to enroll 2600 patients from April 2015 through September 2018 in 17 countries. The protocol describes inclusion of patients started on treatment with bedaquiline- or delamanid- containing regimens under routine care, who consented to participate in the endTB observational study. Patient follow-up was according to routine monitoring schedules recommended for patients receiving bedaquiline or delamanid as implemented at each endTB site. Therefore, no additional tests were performed as a part of the study. Data were to be collected in a customized, open-source electronic medical record (EMR) system developed as a part of the endTB Project across all 17 countries. The endTB observational study will generate evidence on safety and efficacy of bedaquiline- and delamanid-containing regimens in a large, extremely heterogeneous group of MDR-TB patients, from 17 epidemiologically diverse countries. The systematic, prospective data collection of repeated effectiveness and safety measures, and analyses performed on these data, will improve the quality of evidence available to inform MDR-TB treatment and policy decisions. Further, the resources available to countries through implementation of the endTB project will have permitted countries to: gain experience with the use of these drugs in MDR-TB regimens, improve local capacity to record and report adverse events (pharmacovigilance), and enhance significantly the body of data available for safety evaluation of these drugs and other novel treatments. This study was registered on 24 August 2017 at clincaltrials.gov (Registration number: NCT03259269).
- Open Access
- 17 April 2019
- Published by Elsevier in The Lancet Global Health
- Vol. 7 (6) , e706-E706
Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis
- 17 April 2019
- Published by Elsevier in The Lancet Global Health
- Vol. 7 (6) , e706-E706
Open AccessNow is the time for shorter all-oral regimens for multidrug-resistant tuberculosis
- Open Access
- 2 August 2016
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 13 (8) , e1002062
Multidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?
Kwonjune Seung and colleagues describe the Eugene Bell Foundation's experience of treating MDR-TB in North Korea.
- 2 August 2016
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 13 (8) , e1002062
Open AccessMultidrug-Resistant Tuberculosis Treatment in North Korea: Is Scale-Up Possible?
Kwonjune Seung and colleagues describe the Eugene Bell Foundation's experience of treating MDR-TB in North Korea.
- Top Cited PapersOpen Access
- 27 April 2015
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 5 (9) , a017863
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-TB. Extensively drug-resistant (XDR) TB refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. Although patients harboring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen. Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.
- 27 April 2015
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 5 (9) , a017863
Top Cited PapersOpen AccessMultidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-TB. Extensively drug-resistant (XDR) TB refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. Although patients harboring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen. Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.
- 1 May 2014
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 20 (5) , 441-446
Salvage therapy for multidrug-resistant tuberculosis
- 1 May 2014
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 20 (5) , 441-446
Salvage therapy for multidrug-resistant tuberculosis
- Open Access
- 14 January 2014
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 6
Integrated care as a means to improve primary care delivery for adults and adolescents in the developing world: a critical analysis of Integrated Management of Adolescent and Adult Illness (IMAI)
More than three decades after the 1978 Declaration of Alma-Ata enshrined the goal of ‘health for all’, high-quality primary care services remain undelivered to the great majority of the world’s poor. This failure to effectively reach the most vulnerable populations has been, in part, a failure to develop and implement appropriate and effective primary care delivery models. This paper examines a root cause of these failures, namely that the inability to achieve clear and practical consensus around the scope and aims of primary care may be contributing to ongoing operational inertia. The present work also examines integrated models of care as a strategy to move beyond conceptual dissonance in primary care and toward implementation. Finally, this paper examines the strengths and weaknesses of a particular model, the World Health Organization’s Integrated Management of Adolescent and Adult Illness (IMAI), and its potential as a guidepost toward improving the quality of primary care delivery in poor settings.
- 14 January 2014
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 6
Open AccessIntegrated care as a means to improve primary care delivery for adults and adolescents in the developing world: a critical analysis of Integrated Management of Adolescent and Adult Illness (IMAI)
More than three decades after the 1978 Declaration of Alma-Ata enshrined the goal of ‘health for all’, high-quality primary care services remain undelivered to the great majority of the world’s poor. This failure to effectively reach the most vulnerable populations has been, in part, a failure to develop and implement appropriate and effective primary care delivery models. This paper examines a root cause of these failures, namely that the inability to achieve clear and practical consensus around the scope and aims of primary care may be contributing to ongoing operational inertia. The present work also examines integrated models of care as a strategy to move beyond conceptual dissonance in primary care and toward implementation. Finally, this paper examines the strengths and weaknesses of a particular model, the World Health Organization’s Integrated Management of Adolescent and Adult Illness (IMAI), and its potential as a guidepost toward improving the quality of primary care delivery in poor settings.
- 1 March 2012
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 16 (3) , 418-422
Distribution of adult respiratory illnesses at a primary health centre in Lesotho
SETTING: Primary health centre in the highlands of Lesotho. BACKGROUND: There is limited information about the relative frequencies of common respiratory illnesses in resource-limited settings, particularly in sub-Saharan Africa. OBJECTIVE: To examine whether the distribution of respiratory illnesses in this region is unique due to the high prevalence of human immunodeficiency virus infection. DESIGN: In a prospective, cross-sectional study of adults and adolescents with cough or difficulty breathing recruited from the waiting areas of the health centre, the primary outcome was the respiratory diagnosis for each participant, which was based on history, physical examination, response to antibiotics and the results of chest radiography (CXR) and sputum examinations. RESULTS: Acute respiratory infections accounted for 65% of all diagnoses among 696 patients who were evaluated by a clinician and CXR. Pneumonia accounted for 10% of all diagnoses, and confirmed or probable tuberculosis (TB) accounted for 13%. Chronic respiratory conditions, including asthma, chronic obstructive pulmonary disease, silicosis and old TB, accounted for 14% of all diagnoses. Excluding 61 patients with an uninterpretable CXR, 36% (228) of the participants had significant pathology on CXR. CONCLUSION: A high proportion of patients presenting to a primary health centre in Lesotho with routine respiratory complaints have serious respiratory illnesses.
- 1 March 2012
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 16 (3) , 418-422
Distribution of adult respiratory illnesses at a primary health centre in Lesotho
SETTING: Primary health centre in the highlands of Lesotho. BACKGROUND: There is limited information about the relative frequencies of common respiratory illnesses in resource-limited settings, particularly in sub-Saharan Africa. OBJECTIVE: To examine whether the distribution of respiratory illnesses in this region is unique due to the high prevalence of human immunodeficiency virus infection. DESIGN: In a prospective, cross-sectional study of adults and adolescents with cough or difficulty breathing recruited from the waiting areas of the health centre, the primary outcome was the respiratory diagnosis for each participant, which was based on history, physical examination, response to antibiotics and the results of chest radiography (CXR) and sputum examinations. RESULTS: Acute respiratory infections accounted for 65% of all diagnoses among 696 patients who were evaluated by a clinician and CXR. Pneumonia accounted for 10% of all diagnoses, and confirmed or probable tuberculosis (TB) accounted for 13%. Chronic respiratory conditions, including asthma, chronic obstructive pulmonary disease, silicosis and old TB, accounted for 14% of all diagnoses. Excluding 61 patients with an uninterpretable CXR, 36% (228) of the participants had significant pathology on CXR. CONCLUSION: A high proportion of patients presenting to a primary health centre in Lesotho with routine respiratory complaints have serious respiratory illnesses.
- Open Access
- 15 August 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (4) , 379-380
Does My Patient Have Multidrug‐Resistant Tuberculosis?
After how long in tuberculosis (TB) treatment can I expected my patient to have negative smear or culture results? This is a common concern of clinicians throughout the world. One worry is about the infectiousness of the patient with TB. A patient who is smear negative can be expected to be less infectious than one who is smear positive, and this may indicate that he or she is safe to reenter the home and society. However, an even greater worry is about drug resistance, especially in an era when multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains are increasingly common. In developing countries, most TB is still treated empirically, without the benefit of drug susceptibility tests (DSTs). In these settings, failure to respond to first-line TB drugs is the only way to identify patients at risk for MDR TB. The question posed is a crucial one when evaluating a patient who is still smear positive after completing 2 months of treatment. Is the patient just a slow converter or does the patient have MDR TB?
- 15 August 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (4) , 379-380
Open AccessDoes My Patient Have Multidrug‐Resistant Tuberculosis?
After how long in tuberculosis (TB) treatment can I expected my patient to have negative smear or culture results? This is a common concern of clinicians throughout the world. One worry is about the infectiousness of the patient with TB. A patient who is smear negative can be expected to be less infectious than one who is smear positive, and this may indicate that he or she is safe to reenter the home and society. However, an even greater worry is about drug resistance, especially in an era when multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains are increasingly common. In developing countries, most TB is still treated empirically, without the benefit of drug susceptibility tests (DSTs). In these settings, failure to respond to first-line TB drugs is the only way to identify patients at risk for MDR TB. The question posed is a crucial one when evaluating a patient who is still smear positive after completing 2 months of treatment. Is the patient just a slow converter or does the patient have MDR TB?